|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pravastatin#Warnings]] |
| {{Pravastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| ===Skeletal Muscle===
| |
| | |
| Rare cases of [[rhabdomyolysis]] with acute renal failure secondary to [[myoglobinuria]] have been reported with pravastatin and other drugs in this class. A history of renal impairment may be a risk factor for the development of [[rhabdomyolysis]]. Such patients merit closer monitoring for skeletal muscle effects.
| |
| | |
| Uncomplicated [[myalgia]] has also been reported in pravastatin-treated patients [see Adverse Reactions (6)]. [[Myopathy]], defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), was rare (<0.1%) in pravastatin clinical trials. [[Myopathy]] should be considered in any patient with diffuse [[myalgias]], muscle tenderness or weakness, and/or marked elevation of CPK. Predisposing factors include advanced age (≥65), uncontrolled [[hypothyroidism]], and renal impairment.
| |
| | |
| There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune [[myopathy]], associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum CPK, which persist despite discontinuation of [[statin]] treatment; muscle biopsy showing necrotizing [[myopathy]] without significant inflammation and improvement with immunosuppressive agents.
| |
| | |
| All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing PRAVACHOL.
| |
| | |
| Pravastatin therapy should be discontinued if markedly elevated CPK levels occur or [[myopathy]] is diagnosed or suspected. Pravastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to [[rhabdomyolysis]], e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. | |
| | |
| The risk of [[myopathy]] during treatment with statins is increased with concurrent therapy with either erythromycin, cyclosporine, niacin, or fibrates. However, neither [[myopathy]] nor significant increases in CPK levels have been observed in 3 reports involving a total of 100 post-transplant patients (24 renal and 76 cardiac) treated for up to 2 years concurrently with pravastatin 10 to 40 mg and cyclosporine. Some of these patients also received other concomitant immunosuppressive therapies. Further, in clinical trials involving small numbers of patients who were treated concurrently with pravastatin and niacin, there were no reports of [[myopathy]]. Also, [[myopathy]] was not reported in a trial of combination pravastatin (40 mg/day) and gemfibrozil (1200 mg/day), although 4 of 75 patients on the combination showed marked CPK elevations versus 1 of 73 patients receiving placebo. There was a trend toward more frequent CPK elevations and patient withdrawals due to musculoskeletal symptoms in the group receiving combined treatment as compared with the groups receiving placebo, gemfibrozil, or pravastatin monotherapy. The use of fibrates alone may occasionally be associated with [[myopathy]]. The benefit of further alterations in lipid levels by the combined use of PRAVACHOL with fibrates should be carefully weighed against the potential risks of this combination.
| |
| | |
| Cases of [[myopathy]], including [[rhabdomyolysis]], have been reported with pravastatin coadministered with [[colchicine]], and caution should be exercised when prescribing pravastatin with [[colchicine]] [see Drug Interactions (7.3)].
| |
| | |
| ===Liver===
| |
| | |
| [[Statins]], like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. In 3 long-term (4.8-5.9 years), placebo-controlled clinical trials (WOS, LIPID, CARE), 19,592 subjects (19,768 randomized) were exposed to pravastatin or placebo [see Clinical Studies (14)]. In an analysis of serum transaminase values (ALT, AST), incidences of marked abnormalities were compared between the pravastatin and placebo treatment groups; a marked abnormality was defined as a post-treatment test value greater than 3 times the upper limit of normal for subjects with pretreatment values less than or equal to the upper limit of normal, or 4 times the pretreatment value for subjects with pretreatment values greater than the upper limit of normal but less than 1.5 times the upper limit of normal. Marked abnormalities of ALT or AST occurred with similar low frequency (≤1.2%) in both treatment groups. Overall, clinical trial experience showed that liver function test abnormalities observed during pravastatin therapy were usually asymptomatic, not associated with [[cholestasis]], and did not appear to be related to treatment duration. In a 320-patient placebo-controlled clinical trial, subjects with chronic (>6 months) stable liver disease, due primarily to hepatitis C or non-alcoholic fatty liver disease, were treated with 80 mg pravastatin or placebo for up to 9 months. The primary safety endpoint was the proportion of subjects with at least one ALT ≥2 times the upper limit of normal for those with normal ALT (≤ the upper limit of normal) at baseline or a doubling of the baseline ALT for those with elevated ALT (> the upper limit of normal) at baseline. By Week 36, 12 out of 160 (7.5%) subjects treated with pravastatin met the prespecified safety ALT endpoint compared to 20 out of 160 (12.5%) subjects receiving placebo. Conclusions regarding liver safety are limited since the study was not large enough to establish similarity between groups (with 95% confidence) in the rates of ALT elevation.
| |
| | |
| It is recommended that liver function tests be performed prior to the initiation of therapy and when clinically indicated.
| |
| | |
| Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of pravastatin [see Contraindications (4.2)]. Caution should be exercised when pravastatin is administered to patients who have a recent (<6 months) history of liver disease, have signs that may suggest liver disease (e.g., unexplained aminotransferase elevations, [[jaundice]]), or are heavy users of alcohol.
| |
| | |
| There have been rare postmarketing reports of fatal and non-fatal [[hepatic failure]] in patients taking statins, including pravastatin. If serious liver injury with clinical symptoms and/or [[hyperbilirubinemia]] or [[jaundice]] occurs during treatment with PRAVACHOL, promptly interrupt therapy. If an alternate etiology is not found do not restart PRAVACHOL.
| |
| | |
| ===Endocrine Function===
| |
| | |
| [[Statins]] interfere with [[cholesterol]] synthesis and lower circulating [[cholesterol]] levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Results of clinical trials with pravastatin in males and post-menopausal females were inconsistent with regard to possible effects of the drug on basal steroid hormone levels. In a study of 21 males, the mean testosterone response to human chorionic gonadotropin was significantly reduced (p<0.004) after 16 weeks of treatment with 40 mg of pravastatin. However, the percentage of patients showing a ≥50% rise in plasma testosterone after human chorionic gonadotropin stimulation did not change significantly after therapy in these patients. The effects of statins on spermatogenesis and fertility have not been studied in adequate numbers of patients. The effects, if any, of pravastatin on the pituitary-gonadal axis in pre-menopausal females are unknown. Patients treated with pravastatin who display clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should also be exercised if a statin or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., [[ketoconazole]], [[spironolactone]], [[cimetidine]]) that may diminish the levels or activity of steroid hormones.
| |
| | |
| In a placebo-controlled study of 214 pediatric patients with HeFH, of which 106 were treated with pravastatin (20 mg in the children aged 8-13 years and 40 mg in the adolescents aged 14-18 years) for 2 years, there were no detectable differences seen in any of the endocrine parameters (ACTH, cortisol, DHEAS, FSH, LH, TSH, estradiol [girls] or testosterone [boys]) relative to placebo. There were no detectable differences seen in height and weight changes, testicular volume changes, or Tanner score relative to placebo.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRAVACHOL (PRAVASTATIN SODIUM) TABLET [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da | publisher = | date = | accessdate = 18 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Naphthalenes]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |